Month: March 2022

XR Immersive Tech Issues Corporate Update

Written by Customer Service on March 17, 2022. Posted in Public Companies.

VANCOUVER, British Columbia, March 17, 2022 (GLOBE NEWSWIRE) — XR Immersive Tech Inc. (“Immersive Tech”, or the “Company”) (CSE:VRAR) (FSE:79W) (OTCQB: FNTTF) is pleased to provide the following corporate update on its operations as it continues to build its next-generation Immersive Entertainment Platform of Metaverse tools and VR experiences for the out-of-home entertainment industry. The Company is focused on three core pillars of its business in 2022: 1) Hyper-immersive™ VR Attractions; 2) Uncontained O/S which is the software powering our attractions and used by our global network of operators and creators; and 3) our SynthesisVR Network engine powering over 300 VR arcade centers globally. Immersive Tech would like to share some of the highlights achieved over the past year, in the first quarter of 2022 to-date, as well as...

Iceland Seafood International hf: Annual Report 2021 and AGM webcast

Written by Customer Service on March 17, 2022. Posted in Public Companies.

Attached is a PDF version of Iceland Seafood’s Annual Report for 2021. As previously announced the Annual General Meeting of Iceland Seafood International hf will be held today at 4pm at Hilton Reykjavík Nordica, Suðurlandsbraut 2, 108 Reykjavík. The meeting will also be webcasted live, the link for the webcast is the following: https://vimeo.com/event/1939619/embed/5231c90749AttachmentICEASEA Annual Report 2021

Monarch Confirms Continuity of the “Q Zone” Over 150 m Along Strike With 19.05 g/t Au Over 6.8 m (22.3 ft)

Written by Customer Service on March 17, 2022. Posted in Public Companies.

Section 1: Vertical section looking N275 showing the location of Q Zone’s extension Section 1: Vertical section looking N275 showing the location of Q Zone’s extensionLongitudinal 1: Vertical longitudinal section looking N358 showing the location of Q Zone’s extension Longitudinal 1: Vertical longitudinal section looking N358 showing the location of Q Zone’s extensionMonarch has received additional high-grade assays from its 2021 underground drilling program, which include 19.05 g/t Au over 6.8 m, including 12.56 g/t Au over 1.4 m and 54.68 g/t Au over 2.0 m (BEU-21-30-032). These results are from the underground drilling program currently being carried out in the lower part of the mine. The “Q Zone” was mined most recently in 2019 and has proven to be one of the most prolific and continuous ore zones in the mine. These diamond...

Lithium Americas Reports 2021 Full Year and Fourth Quarter Results

Written by Customer Service on March 17, 2022. Posted in Earnings Releases And Operating Results.

VANCOUVER, British Columbia, March 17, 2022 (GLOBE NEWSWIRE) — Lithium Americas Corp. (TSX: LAC) (NYSE: LAC) (“Lithium Americas” or the “Company”) has reported financial and operating results for the fourth quarter and year ended December 31, 2021. HIGHLIGHTS Argentina Caucharí-OlarozConstruction continues to advance with a revised timeline; currently the project is approximately 85% complete and commissioning is targeted to commence in H2 2022.1,500 workers are on site with 100% of the workforce having received at least two doses of a COVID-19 vaccine. Around the end of 2021, construction activities were impacted by COVID-19 Omicron disruptions impacting supply chains and availability of the main contractor. Activities have returned to normal and the Company continues to monitor the situation closely. Additional resources...

ProMIS Neurosciences Announces Fiscal Year 2021 Results

Written by Customer Service on March 17, 2022. Posted in Earnings Releases And Operating Results.

TORONTO, Ontario and CAMBRIDGE, Massachusetts , March 17, 2022 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the fiscal year ended December 31, 2021. “2021 was an excellent year for ProMIS including strong capital formation which enabled us to advance and expand our portfolio of differentiated therapeutic product candidates such as Alzheimer’s disease (AD), ALS, and Schizophrenia,” said Gene Williams, ProMIS’ Chairman and CEO. “We feel privileged that leading global experts continue to join our Scientific Advisory...

Destination XL Group, Inc. Reports Fiscal 2021 Fourth-Quarter and Full-Year Financial Results

Written by Customer Service on March 17, 2022. Posted in Earnings Releases And Operating Results.

Reports Record Annual Sales and Profit;Full-Year Sales of $505 Million, Net Income of $56.7 million, $0.83 EPS,Adjusted EBITDA of $76.9 millionAnnounces $15.0 Million Stock Repurchase Program CANTON, Mass., March 17, 2022 (GLOBE NEWSWIRE) — Destination XL Group, Inc. (NASDAQ: DXLG), the largest omni-channel specialty retailer of big and tall men’s apparel, today reported financial results for the fourth quarter and fiscal year 2021. Fourth Quarter HighlightsTotal sales for the fourth quarter were $133.5 million, up 33.3% from $100.1 million for fiscal 2020 and up 1.7% from $131.2 million for fiscal 2019. Comparable sales increased 41.5% as compared to fiscal 2020 and 9.4% as compared to fiscal 2019. Net income for the fourth quarter was $9.9 million, or $0.14 per diluted share, as compared to a net loss of $(5.1) million, or...

Synlogic Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Written by Customer Service on March 17, 2022. Posted in Earnings Releases And Operating Results.

– Phenylketonuria (PKU) program on track for Phase 3 trial initiation in H2 2022 – – Clinical readouts anticipated for PKU program in H1 2022 and in homocystinuria and enteric hyperoxaluria in H2 2022 – – $136.6 million in cash, cash equivalents and marketable securities support projected runway into 2024 – – Conference call and webcast at 8:30 a.m. ET today – CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) — Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today reported financial results for the fourth quarter and full year ending December 31, 2021 and provided an update on pipeline programs. “2021 was a transformational year for Synlogic highlighted by proof of concept...

MediWound Reports Fourth Quarter and Full Year 2021 Financial Results

Written by Customer Service on March 17, 2022. Posted in Earnings Releases And Operating Results.

Full-Year 2021 Total Revenues of $23.8 Million; Product Revenues Up 46% Positive Top-Line Data for EscharEx Phase 2 Clinical Trial, with Full Data Set Anticipated in Second Quarter 2022 Raised Gross Proceeds of $10 Million through Public Equity Offering Conference Call Begins Today at 8:30 am ET YAVNE, Israel, March 17, 2022 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update. Fourth Quarter, Full-Year 2021 and Recent Weeks Financial Highlights:Total revenues for 2021 were $23.8 million; compared to $21.8 million in 2020 Product revenues in 2021 increased by...

Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

Written by Customer Service on March 17, 2022. Posted in Earnings Releases And Operating Results.

Over $140M in capital raised in initial public offering in 2021; Cash runway through first half 2024 Advanced IK-930, lead targeted oncology program, into the clinic, continuing leadership in the Hippo pathway therapeutic landscape Expanded IK-175 clinical trial cohorts for urothelial carcinoma patients enriched for nuclear AHR positivity; Second trial indication announced in head & neck squamous cell carcinoma Initiated multiple new discovery programs in the RAS & Hippo pathways Clinical data updates across the immune-signaling pipeline planned for second half 2022 BOSTON, March 17, 2022 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena™”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the fourth quarter and full...

Aadi Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Written by Customer Service on March 17, 2022. Posted in Earnings Releases And Operating Results.

-FYARRO™ approved November 22, 2021 and launched February 23, 2022- –FYARRO added to NCCN® Guidelines as the only preferred therapy to treat malignant PEComa- -PRECISION 1 tumor agnostic study for TSC1 or TSC2 alterations open for enrollment- –Ended fourth quarter 2021 with $149.0 million in cash and cash equivalents- LOS ANGELES, March 17, 2022 (GLOBE NEWSWIRE) — Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update. “We are well-positioned in 2022 with a strong team, a solid balance sheet, and a highly promising recently approved drug,” stated...

Month: March 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals